Kotra Industries Berhad, an investment holding company, (0002) Fair Value & Analysis
Healthcare · MY · Market cap 558M MYR
Fair value as of: Jun 25, 2026
Analysis
Kotra Industries Berhad, an investment holding company, (0002) currently trades at 3.75 MYR, while our model-based Fair Value estimate is 3.90 MYR — implying the stock looks roughly 4.0% undervalued today. We read business quality at 92/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
Kotra Industries Berhad, an investment holding company, develops, manufactures, and trades in pharmaceutical and healthcare products in Malaysia. The company provides nutraceutical products, including various health supplement products under the Appeton brand for children, expectant mothers, and senior citizens. It also offers various pharmaceutical products in the areas of pediatric care, anti-infective, gastroenterology, and dermatology under the Axcel brand; sterile antibiotic injectables under the Vaxcel brand; asthma control products under the Arite brand; and fungal infection treatment products under the Creobic brand. In addition, it provides treatment of pain, such as fever, migraine, joint pain, headache, and backpain under the AxPain brand. The company was founded in 1982 and is headquartered in Malacca, Malaysia. Kotra Industries Berhad is a subsidiary of Piong Nam Kim Holdings Sdn. Bhd.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Kotra Industries Berhad, an investment holding company, (0002) undervalued?
What is the fair value of 0002?
What is the quality score of 0002?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.